Clinical Trial Results with OROS® Hydromorphone

Slides:

Advertisements

Similar presentations

Treatment of postherpetic neuralgia: a review of therapeutic options Charles E. Argoff, MD, Nathaniel Katz, MD, Miroslav Backonja, MD Journal of Pain and.

Advertisements

Management of Phantom Pain with a Textile, Electromagnetically-Acting Stump Liner: A Randomized, Double-Blind, Crossover Study Uwe Kern, MD, Bernd Altkemper,

Oropharyngeal Mucositis Pain Treatment with Transdermal Buprenorphine in Patients After Allogeneic Stem Cell Transplantation Samuel Vokurka, MD, PhD

One-Year rTMS Treatment for Refractory Trigeminal Neuralgia

Chronic Pain Management in Older Adults: Special Considerations

Managing Metastatic Bone Pain: The Role of Bisphosphonates

Switching Breast Cancer Patients with Progressive Bone Metastases to Third- Generation Bisphosphonates: Measuring Impact Using the Functional Assessment.

Neurotoxicity from Chronic Opioid Therapy After Successful Palliative Treatment for Painful Bone Metastases Andrew Broadbent, BMedSc, MBChB, FRACP, FAChPM,

Winston C. -V. Parris, MD, Benjamin W. Johnson, MD, Marilyn K

Managing Metastatic Bone Pain: The Role of Bisphosphonates

Wen Jing Chung, MD, MS, Gregory H. Pharo, DO

Chronic Pain Management in Older Adults: Special Considerations

A Case Series of Patients Using Medicinal Marihuana for Management of Chronic Pain Under the Canadian Marihuana Medical Access Regulations Mary E. Lynch,

Opioids for Cancer Breakthrough Pain: A Pilot Study Reporting Patient Assessment of Time to Meaningful Pain Relief Giovambattista Zeppetella, FRCP Journal.

Long-Term Opioid Therapy for Chronic Noncancer Pain: A Systematic Review and Meta-Analysis of Efficacy and Safety Meredith Noble, MS, Stephen J. Tregear,

Patterns of Pain and Interference in Patients with Painful Bone Metastases: A Brief Pain Inventory Validation Study Jackson S.Y. Wu, MD, MSc, FRCPC,

Efficacy and Safety of a Once-Daily Morphine Formulation in Chronic, Moderate-to- Severe Osteoarthritis Pain Jacques R. Caldwell, MD, Ronald J. Rapoport,

Reliability, Validity, and Responsiveness of the Daily Sleep Interference Scale Among Diabetic Peripheral Neuropathy and Postherpetic Neuralgia Patients

David M. Simpson, MD, Lydia Estanislao, MD, Stephen J

Establishing Mild, Moderate, and Severe Scores for Cancer-Related Symptoms: How Consistent and Clinically Meaningful Are Interference-Based Severity Cut-Points?

Consistency of Efficacy, Patient Acceptability, and Nasal Tolerability of Fentanyl Pectin Nasal Spray Compared with Immediate-Release Morphine Sulfate.

Use of the Cumulative Proportion of Responders Analysis Graph to Present Pain Data Over a Range of Cut-Off Points: Making Clinical Trial Data More Understandable

What Influences Patients’ Decisions on Artificial Hydration at the End of Life? A Q- Methodology Study Catherine Malia, MSc, Michael I. Bennett, MB, ChB,

Once-Daily Gastroretentive Gabapentin for Postherpetic Neuralgia: Integrated Efficacy, Time to Onset of Pain Relief and Safety Analyses of Data From Two.

Oropharyngeal Mucositis Pain Treatment with Transdermal Buprenorphine in Patients After Allogeneic Stem Cell Transplantation Samuel Vokurka, MD, PhD

Symptomatic Therapy of Dyspnea with Strong Opioids and Its Effect on Ventilation in Palliative Care Patients Katri Elina Clemens, MD, PhD, Eberhard Klaschik,

Eduardo Bruera, MD, Raul Sala, MD, Odette Spruyt, MD, J

Efficacy of transdermal nitroglycerin combined with etodolac for the treatment of chronic post-thoracotomy pain: An open-label prospective clinical trial

Jean-Pierre Van Buyten, MD Journal of Pain and Symptom Management

Efficacy and safety of extended-release, once-daily tramadol in chronic pain: a randomized 12-week clinical trial in osteoarthritis of the knee Najib.

What Can We Learn About the Spiritual Needs of Palliative Care Patients From the Research Literature? Mark Cobb, MA, Christopher Dowrick, MD, FRCGP,

One-Year rTMS Treatment for Refractory Trigeminal Neuralgia

Transdermal Fentanyl for Chronic Pain in AIDS

Parent Perceptions of Child Vulnerability Are Associated With Functioning and Health Care Use in Children With Chronic Pain Mark Connelly, PhD, Kelly.

David Clark, PhD, Michael Wright, PhD

Redefining Appropriate Treatment Expectations

Clinical Response to an Outpatient Palliative Care Consultation in Patients With Advanced Cancer and Cancer Pain Sriram Yennurajalingam, MD, Jung Hun.

Long-Term Safety and Efficacy of Morphine Sulfate and Naltrexone Hydrochloride Extended Release Capsules, a Novel Formulation Containing Morphine and.

Treatment of Cancer Pain with Noninvasive Brain Stimulation

Changes in Symptom Intensity Among Cancer Patients Receiving Outpatient Palliative Care Jung Hun Kang, MD, PhD, Jung Hye Kwon, MD, PhD, David Hui, MD,

Characterization of the early pharmacodynamic profile of oral methadone for cancer- related breakthrough pain: a pilot study Kim Fisher, PhD, Carla Stiles,

Jodi L. Hannan, MD, Steven M. Radwany, MD, Terry Albanese, PhD

Charles S. Cleeland, PhD, Jeff A. Sloan, PhD

Paul A. Sloan, MD, Dwight E. Moulin, MD, FRCP(C), Helen Hays, MD

Evaluation of Methadone Absorption After Topical Administration to Hospice Patients Robert K. Sylvester, PharmD, Caroline Schauer, RN, John Thomas, MD,

Ecological Momentary Assessment of Fatigue in Patients Receiving Intensive Cancer Therapy Eileen Danaher Hacker, PhD, APN, AOCN, Carol Estwing Ferrans,

Barrie R. Cassileth, PhD, Andrew J. Vickers, PhD

The Role of a Low-Dose Ketamine-Midazolam Regimen in the Management of Severe Painful Crisis in Patients With Sickle Cell Disease Qutaiba A. Tawfic,

Robert L. Jayes, MD, Robert M. Arnold, MD, Erik K. Fromme, MD

Do Interference-Based Cut-Points Differentiate Mild, Moderate, and Severe Levels of 16 Cancer-Related Symptoms Over Time? Sangchoon Jeon, MS, Charles.

Safety and Tolerability of Once-Daily OROS® Hydromorphone Extended-Release in Opioid-Tolerant Adults With Moderate-to-Severe Chronic Cancer and Noncancer.

The Spiritual Needs Assessment for Patients (SNAP): Development and Validation of a Comprehensive Instrument to Assess Unmet Spiritual Needs Rashmi K.

Armodafinil for Sarcoidosis-Associated Fatigue: A Double-Blind, Placebo-Controlled, Crossover Trial Elyse E. Lower, MD, Atul Malhotra, MD, Victoria Surdulescu,

Is the B12/CRP Index More Accurate Than You at Predicting Life Expectancy in Advanced Cancer Patients? Filipa Tavares, MD Journal of Pain and Symptom.

Association Between Symptom Distress and Survival in Outpatients Seen in a Palliative Care Cancer Center J. Lynn Palmer, PhD, Michael J. Fisch, MD, MPH

Comparative Efficacy of Oral Extended-Release Hydromorphone and Immediate- Release Hydromorphone in Patients with Persistent Moderate to Severe Pain: Two.

Carmen R. Green, MD, Laura Montague, BS, Tamera A. Hart-Johnson, MS

Tomoyuki Kawada, MD Journal of Pain and Symptom Management

Clinical and Economic Impact of Palliative Care Consultation

Providing Constant Analgesia with OROS® Hydromorphone

James T. Lin, MD, Paul Mathew, MD

Hydromorphone Journal of Pain and Symptom Management

A Multicenter Study Comparing Two Numerical Versions of the Edmonton Symptom Assessment System in Palliative Care Patients Sharon M. Watanabe, MD, Cheryl.

Nina D. Wagner-Johnston, MD, Kathryn A. Carson, ScM, Stuart A

Management of Phantom Pain with a Textile, Electromagnetically-Acting Stump Liner: A Randomized, Double-Blind, Crossover Study Uwe Kern, MD, Bernd Altkemper,

Amy P. Abernethy, MD Journal of Pain and Symptom Management

Scrambler Therapy May Relieve Chronic Neuropathic Pain More Effectively Than Guideline-Based Drug Management: Results of a Pilot, Randomized, Controlled.

Long-Term Opioid Therapy for Chronic Noncancer Pain: A Systematic Review and Meta-Analysis of Efficacy and Safety Meredith Noble, MS, Stephen J. Tregear,

A Multicenter Study Comparing Two Numerical Versions of the Edmonton Symptom Assessment System in Palliative Care Patients Sharon M. Watanabe, MD, Cheryl.

Use of Pregabalin in the Management of Chronic Uremic Pruritus

Presentation transcript:

Clinical Trial Results with OROS® Hydromorphone Mark S. Wallace, MD, John Thipphawong, MD Journal of Pain and Symptom Management Volume 33, Issue 2, Pages S25-S32 (February 2007) DOI: 10.1016/j.jpainsymman.2006.09.008 Copyright © 2007 U.S. Cancer Pain Relief Committee Terms and Conditions

Fig. 1 Interference of chronic pain with daily activities before and after oral administration of OROS® hydromorphone once daily for at least 7 days.6 Journal of Pain and Symptom Management 2007 33, S25-S32DOI: (10.1016/j.jpainsymman.2006.09.008) Copyright © 2007 U.S. Cancer Pain Relief Committee Terms and Conditions

Fig. 2 Interference of chronic cancer pain with daily activities after OROS® hydromorphone once daily or controlled-release morphine twice daily for ≥12 days.3 BPI scored from 0 (no interference) to 10 (complete interference). Journal of Pain and Symptom Management 2007 33, S25-S32DOI: (10.1016/j.jpainsymman.2006.09.008) Copyright © 2007 U.S. Cancer Pain Relief Committee Terms and Conditions

Fig. 3 Breakthrough medication use in patients with chronic cancer pain.3 Journal of Pain and Symptom Management 2007 33, S25-S32DOI: (10.1016/j.jpainsymman.2006.09.008) Copyright © 2007 U.S. Cancer Pain Relief Committee Terms and Conditions

Fig. 4 Global evaluation of therapy among patients with chronic cancer pain treated with once-daily OROS® hydromorphone or twice-daily controlled-release morphine.3 Journal of Pain and Symptom Management 2007 33, S25-S32DOI: (10.1016/j.jpainsymman.2006.09.008) Copyright © 2007 U.S. Cancer Pain Relief Committee Terms and Conditions

Fig. 5 Improvements in overall pain relief among patients with chronic low back pain treated with OROS® hydromorphone.11 Journal of Pain and Symptom Management 2007 33, S25-S32DOI: (10.1016/j.jpainsymman.2006.09.008) Copyright © 2007 U.S. Cancer Pain Relief Committee Terms and Conditions

Fig. 6 BPI pain severity in patients with low back pain treated with OROS® hydromorphone in a 7-week, open-label study.11 BPI scored from 0 (no interference) to 10 (complete interference). Journal of Pain and Symptom Management 2007 33, S25-S32DOI: (10.1016/j.jpainsymman.2006.09.008) Copyright © 2007 U.S. Cancer Pain Relief Committee Terms and Conditions

Fig. 7 Effect of OROS® hydromorphone on quality of life in patients with moderate to severe low back pain.11 Journal of Pain and Symptom Management 2007 33, S25-S32DOI: (10.1016/j.jpainsymman.2006.09.008) Copyright © 2007 U.S. Cancer Pain Relief Committee Terms and Conditions

Fig. 8 Mean changes from baseline pain relief and pain intensity associated with OROS® hydromorphone and extended-release oxycodone in patients with chronic osteoarthritis pain. Journal of Pain and Symptom Management 2007 33, S25-S32DOI: (10.1016/j.jpainsymman.2006.09.008) Copyright © 2007 U.S. Cancer Pain Relief Committee Terms and Conditions

Fig. 9 Mean changes from baseline in MOS sleep Indices I and II after treatment with OROS® hydromorphone or extended-release oxycodone in patients with chronic osteoarthritis pain. Sleep problems Index I is derived from items 4 (get enough sleep to feel rested upon waking in the morning), 5 (awaken short of breath or with a headache), 7 (have trouble falling asleep), 8 (awaken during your sleep time and have trouble falling asleep again), 9 (have trouble staying awake during the day), and 12 (get the amount of sleep you needed) of the MOS sleep assessment; higher scores indicate greater sleep problems. Sleep problems Index II is derived from items 1 (time to fall asleep), 3 (feel that sleep was not quiet), 4, 5, 6 (feel drowsy or sleepy during the day), 7, 8, 9, and 12 of the MOS sleep assessment; higher scores indicate greater sleep problems. Journal of Pain and Symptom Management 2007 33, S25-S32DOI: (10.1016/j.jpainsymman.2006.09.008) Copyright © 2007 U.S. Cancer Pain Relief Committee Terms and Conditions